image
Biodexa Pharmaceuticals Plc BDRX
Healthcare - Biotechnology - NASDAQ - GB
Watchlist
$ 3.62
-25.9 %
$ 2.1 M
Market Cap
-0.05
P/E
1. INTRINSIC VALUE

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.[ Read More ]

The intrinsic value of one BDRX stock under the base case scenario is HIDDEN Compared to the current market price of 3.62 USD, Biodexa Pharmaceuticals Plc is HIDDEN

BDRX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart BDRX

image
FINANCIALS
381 K REVENUE
-45.49%
Growth Rates
1Year -45.49%
3Years 3.56%
5Years -27.77%
7Years -16.29%
10Years 9.99%
-8.01 M OPERATING INCOME
10.28%
Growth Rates
1Year 10.28%
3Years 9.10%
5Years 7.47%
7Years 2.62%
10Years -5.94%
-7.08 M NET INCOME
7.54%
Growth Rates
1Year 7.54%
3Years 31.67%
5Years 13.98%
7Years 13.89%
10Years -5.65%
-6.83 M OPERATING CASH FLOW
3.15%
Growth Rates
1Year 3.15%
3Years 9.80%
5Years 12.69%
7Years 8.88%
10Years -4.40%
-265 K INVESTING CASH FLOW
-20.45%
Growth Rates
1Year -20.45%
3Years -3.32%
5Years -0.58%
7Years 19.43%
10Years -18.15%
10.2 M FINANCING CASH FLOW
21657.45%
Growth Rates
1Year 21657.45%
3Years 49.12%
5Years 29.06%
7Years -5.55%
10Years 4.26%
0 REVENUE
0.00%
Growth Rates
1Year -45.49%
3Years 3.56%
5Years -27.77%
7Years -16.29%
10Years 9.99%
-2.11 M OPERATING INCOME
-0.00%
Growth Rates
1Year 10.28%
3Years 9.10%
5Years 7.47%
7Years 2.62%
10Years -5.94%
-1.65 M NET INCOME
-0.00%
Growth Rates
1Year 7.54%
3Years 31.67%
5Years 13.98%
7Years 13.89%
10Years -5.65%
-2.4 M OPERATING CASH FLOW
-0.00%
Growth Rates
1Year 3.15%
3Years 9.80%
5Years 12.69%
7Years 8.88%
10Years -4.40%
-377 K INVESTING CASH FLOW
-0.00%
Growth Rates
1Year -20.45%
3Years -3.32%
5Years -0.58%
7Years 19.43%
10Years -18.15%
2.32 M FINANCING CASH FLOW
0.00%
Growth Rates
1Year 21657.45%
3Years 49.12%
5Years 29.06%
7Years -5.55%
10Years 4.26%
Balance Sheet Decomposition Biodexa Pharmaceuticals Plc
image
Current Assets 7.03 M
Cash & Short-Term Investments 5.97 M
Receivables 0
Other Current Assets 1.06 M
Non-Current Assets 3.51 M
Long-Term Investments 0
PP&E 571 K
Other Non-Current Assets 2.94 M
Current Liabilities 5.57 M
Accounts Payable 314 K
Short-Term Debt 169 K
Other Current Liabilities 5.09 M
Non-Current Liabilities 295 K
Long-Term Debt 295 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Biodexa Pharmaceuticals Plc
image
Revenue 381 K
Cost Of Revenue 4.07 M
Gross Profit -3.69 M
Operating Expenses 4.33 M
Operating Income -8.01 M
Other Expenses -935 K
Net Income -7.08 M
RATIOS
-967.45% GROSS MARGIN
-967.45%
Averages
1Year -967.45%
3Years -767.94%
5Years -1007.32%
7Years -880.24%
10Years -645.10%
-2103.41% OPERATING MARGIN
-2103.41%
Averages
1Year -2103.41%
3Years -1530.65%
5Years -1876.45%
7Years -1597.52%
10Years -1756.01%
-1858.01% NET MARGIN
-1858.01%
Averages
1Year -1858.01%
3Years -1299.31%
5Years -2344.56%
7Years -1920.19%
10Years -2026.06%
-151.33% ROE
-151.33%
Averages
1Year -151.33%
3Years -148.56%
5Years -164.54%
7Years -131.10%
10Years -97.37%
-67.15% ROA
-67.15%
Averages
1Year -67.15%
3Years -82.67%
5Years -100.72%
7Years -82.59%
10Years -62.36%
-162.02% ROIC
-162.02%
Averages
1Year -162.02%
3Years -182.07%
5Years -152.97%
7Years -124.71%
10Years -94.07%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biodexa Pharmaceuticals Plc
image
Net Income -7.08 M
Depreciation & Amortization 283 K
Capital Expenditures -263 K
Stock-Based Compensation 28 K
Change in Working Capital -49 K
Others -17 K
Free Cash Flow -7.09 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biodexa Pharmaceuticals Plc
image
BDRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Biodexa Pharmaceuticals Plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 4 days ago
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that the Company has been formally notified that the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). As previously disclosed, the Company received notice from Nasdaq on August 27, 2024, informing the Company that it was not in compliance with the Minimum Bid Price Requirement. globenewswire.com - 4 days ago
Notice of General Meeting November 7, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 22 November 2024 at 13:00 GMT was posted to shareholders yesterday. The Board of Directors is proposing two resolutions: Ordinary Resolution       1. globenewswire.com - 1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ: BDRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 2 weeks ago
Levi & Korsinsky Reminds Biodexa Pharmaceuticals Plc Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BDRX NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma. accesswire.com - 2 weeks ago
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (NASDAQ: BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX . globenewswire.com - 2 weeks ago
Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX. accesswire.com - 2 weeks ago
ATTENTION Biodexa Pharmaceuticals Plc Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma. accesswire.com - 2 weeks ago
8. Profile Summary

Biodexa Pharmaceuticals Plc BDRX

image
COUNTRY GB
INDUSTRY Biotechnology
MARKET CAP $ 2.1 M
Dividend Yield 0.00%
Description Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Contact 1 Caspian Point, Cardiff, CF10 4DQ https://www.biodexapharma.com
IPO Date Dec. 7, 2015
Employees 21
Officers Mr. Steve Ellul Chief Business Officer Ms. Nicola Tuckwell Vice President & Head of Clinical Operations Mr. Stephen A. Stamp Chief Executive Officer, Chief Financial Officer, Company Secretary & Director Dr. Daniel Palmer MBA, Ph.D. Vice President of Technology Ms. Fiona Sharp Group Financial Controller